Use of class IC antiarrhythmic drugs in patients with structural heart disease and implantable cardioverter defibrillator.

Maura M ZyllaJulian WolfesRuben SchlebergerDennis LawinMeinhard KieserFlorian ReinkeLars EckardtAndreas RilligChristoph StellbrinkDierk ThomasNorbert FreyPatrick Lugenbiel

Published in: Clinical research in cardiology : official journal of the German Cardiac Society (2024)

In a multicenter cohort of ICD-carriers with SHD, class-IC-AADs were associated with a low rate of pro-arrhythmic effects or cardiovascular mortality. The majority of patients remained free from sustained VA during a follow-up of > 2 years. Further efforts should be made to evaluate the safety of class-IC-AADs in SHD patients receiving contemporary cardiovascular therapy.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
cardiovascular events
stem cells
clinical trial
cross sectional
coronary artery disease
patient reported outcomes
atrial fibrillation
bone marrow